File: b-be-15-bvw2-information-for-the-public-written-by.pdfTrial reference: A Phase 1b/3, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (20130232)Doc type: Information for the public
